Favipiravir is used in treatment of Covid-19 patients. We aimed to share of ocular surface fluorescence in a patient after Favipiravir treatment in this case report. A 20-year-old male patient declared no known systemic disease prior to Covid-19. He applied to us with blurry vision and blue light reflection after Covid-19 treatment with Favipiravir. We observed bilateral fluorescence on his eyes and fluorescence of his nails. Biomicroscopic examination was insignificant. We investigated the fluorescence of favipiravir tablets under ultraviolet light. Drug demonstrated fluorescence. We recorded the favipiravir fluorescence in-vitro. This appears to be a strong evidence in terms of the linkage between the fluorescence of the ocular surface and favipiravir.

中文翻译：

---

法匹拉韦治疗后 Covid -19 患者眼表的荧光：病例报告

法匹拉韦用于治疗 Covid-19 患者。在本病例报告中，我们旨在分享法匹拉韦治疗后患者的眼表荧光。一名 20 岁男性患者在 Covid-19 之前宣布没有已知的全身性疾病。在用 Favipiravir 治疗 Covid-19 后，他以模糊的视力和蓝光反射向我们申请。我们观察到他眼睛的双侧荧光和指甲的荧光。生物显微镜检查无意义。我们研究了法匹拉韦片在紫外光下的荧光。药物显示荧光。我们在体外记录了法匹拉韦荧光。这似乎是眼表荧光与法匹拉韦之间联系的有力证据。